Full Breakdown
Caution Advised: Three Low-Volatility Stocks to Avoid
12/6/2025, 4:00:38 AM
Overview of Low-Volatility Stocks
Low-volatility stocks are often perceived as stable investments, but they may underperform during bullish market conditions. This article highlights three low-volatility stocks—Pfizer (PFE), GameStop (GME), and Aflac (AFL)—that investors should approach with caution due to various underlying issues affecting their growth potential.
Pfizer (PFE): Declining Core Business
Pfizer, a global biopharmaceutical company, has seen a significant decline in its core business performance. Over the past two years, the company has experienced disappointing organic revenue growth, prompting concerns about its need for acquisitions to stimulate future growth. Additionally, Pfizer's free cash flow margin has decreased by 26.5 percentage points over the last five years, indicating increased investments to maintain its market position. Currently, Pfizer trades at $25.69 per share, with a forward price-to-earnings (P/E) ratio of 8.6.
GameStop (GME): Struggles in a Digital Era
GameStop, known for its retail presence in video games and pop culture merchandise, faces challenges as consumers shift towards digital downloads. The company has been closing stores after previously shuttering hundreds, which raises concerns about its brick-and-mortar viability. GameStop's stock remains volatile, influenced by its meme-stock status and significant investments in Bitcoin. At $23.22 per share, GameStop has a forward P/E ratio of 26.2, but its unpredictable nature may deter conservative investors.
Aflac (AFL): Stagnant Earnings Growth
Aflac, a provider of supplemental health and life insurance, has seen its net premiums earned contract by 6.2% annually over the last five years. This trend reflects unfavorable market dynamics, and the company's earnings growth has lagged behind its peers, with an annual increase of only 9.4% over the past two years. Aflac's projected book value per share is expected to remain flat for the next 12 months, suggesting a slowdown in profitability. The stock is currently priced at $108.79, with a forward price-to-book (P/B) ratio of 2.
Criticism & Opposition
Critics argue that while low-volatility stocks can provide a sense of security, their lack of growth potential may not justify their inclusion in an investment portfolio. The performance of Pfizer, GameStop, and Aflac raises questions about their ability to deliver returns that meet or exceed market averages.
Official Statements & Responses
StockStory emphasizes the importance of balancing safety and returns in investment decisions. They caution investors about the potential pitfalls of these low-volatility stocks and recommend exploring higher-quality alternatives that may offer better growth prospects.
Conclusion
Investors should exercise caution when considering Pfizer, GameStop, and Aflac for their portfolios. Each company faces unique challenges that could hinder their growth potential, making them less attractive options in the current market landscape.
